Glimp-M 2 Tablet is a combination oral hypoglycemic agent containing Glimepiride 2 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The synergistic action of these two agents helps achieve better glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Glimp-M 2 is typically prescribed when single-agent therapy is insufficient, providing effective reduction in fasting and postprandial blood glucose levels. It is essential to administer this medication with meals to minimize gastrointestinal side effects commonly associated with Metformin, such as nausea and diarrhea. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during treatment. Contraindications include severe renal or hepatic impairment, metabolic acidosis, and conditions predisposing to hypoxia. Caution is advised in patients with cardiovascular disease or those undergoing radiologic studies involving iodinated contrast agents. Glimp-M 2 Tablet should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.